24/7 Market News Snapshot 20 March, 2025 – Actinium Pharmaceuticals, Inc (NYSE:ATNM)

March 20, 2025

DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NYSE:ATNM) are discussed in this article.
Actinium Pharmaceuticals, Inc. is experiencing significant momentum as it opens trading today at $1.29, reaching a peak of $1.465, representing a remarkable 21.07% surge. This upswing follows a previous close of $1.210, indicating a growing bullish sentiment among investors led by strong trading volume of 634.82K shares. The activity reflects increasing market interest as traders recognize the potential of this biotech innovator, prompting many to add ATNM to their watchlists.

In a pivotal development, Actinium has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) aimed at advancing the use of its lead radiotherapeutic, Actimab-A, in the treatment of acute myeloid leukemia (AML). The partnership’s focus lies in exploring innovative combinations of Actimab-A with targeted therapies such as FLT3 and menin inhibitors, specifically designed to enhance treatment options for patients facing high-risk AML.

This sponsored research agreement will enable thorough investigations into the interaction of Actimab-A and various combinations of targeted therapies, utilizing primary patient-derived samples to assess effectiveness and optimize treatment strategies. Actimab-A has demonstrated promising results in clinical trials involving relapsed and refractory AML patients, notably addressing challenging genetic mutations like TP53.

In a statement, Sandesh Seth, Chairman and CEO of Actinium, expressed enthusiasm regarding the revitalization of the Actimab-A program, reaffirming a commitment to tackle unmet needs within AML, which impacts over 100,000 patients annually. The alpha-emitting mechanism of Actimab-A, capable of inducing lethal DNA breaks in cancer cells, offers a novel therapeutic avenue.

With anticipated data releases planned for the latter half of 2025, Actinium is poised to solidify its position in the oncology landscape, particularly within a multi-billion-dollar market. This collaboration not only emphasizes the company’s dedication to pioneering oncology research but also its ongoing efforts to enhance patient outcomes through innovative treatment solutions.

Related news for (ATNM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.